Pharmaceutical company · BMY

Bristol Myers Squibb
clinical trial
pipeline

Registry checked

Published

Xanomeline/Trospium Chloride is linked to 26 distinct active studies, with 2 Phase 1, 20 Phase 3, 2 Phase 4, 2 without a recorded phase. Deucravacitinib is linked to 22 distinct active studies, with 1 Phase 2, 10 Phase 3, 1 Phase 4, 10 without a recorded phase.

28 active trials lack a mapped primary therapeutic group. The categories and accepted programme links are partial enrichment, so individual study records provide additional context.

Active trial mix

Lead-sponsor scope

256active trials
as lead sponsor
  • Phase 140
  • Phase 256
  • Phase 382
  • Phase 48
  • Phase not recorded70

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

1914 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

02Primary completion

Primary completion moved later by 35 days

2024-09-05 (actual)2024-10-10 (actual)
05 Sept 202410 Oct 2024

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

NCT04908202 · ClinicalTrials.gov
Recorded by ComplyRx
17 Oct 2026
Registry last updated
16 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-022111053
2026-10-030000000
2026-10-040000000
2026-10-050000000
2026-10-062010253
2026-10-071110032
2026-10-080100011
2026-10-091000011
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-130100011
2026-10-140000000
2026-10-150000000
2026-10-160010011
2026-10-170100011
2026-10-180000000
2026-10-190000000
2026-10-200000000
2026-10-210010011
2026-10-220000000
2026-10-230000000
2026-10-240000000
2026-10-250000000
2026-10-260000000
2026-10-270000000
2026-10-280000000
2026-10-290000000
2026-10-300000000
2026-10-310000000
Type totals655121914 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Xanomeline/Trospium Chloride

Cobenfy

26
Active trials
24
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 12
  • Phase 20
  • Phase 320
  • Phase 42
  • Phase not recorded2
Studied condition
Agitation · Alzheimer Disease · Alzheimer's Disease
Next primary completion
01 November 2026 · estimated
Open drug

Deucravacitinib

Sotyktu

22
Active trials
11
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 21
  • Phase 310
  • Phase 41
  • Phase not recorded10
Studied condition
Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) · Juvenile Psoriatic Arthritis · Lupus Erythematosus, Discoid
Next primary completion
18 November 2026 · estimated
Open drug

Mavacamten

CAMZYOS

13
Active trials
8
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 31
  • Phase 42
  • Phase not recorded10
Studied condition
Breastfeeding · Cardiomyopathy · Cardiomyopathy, Hypertrophic
Next primary completion
Not reported
Open drug

Nivolumab

Opdivo

11
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 22
  • Phase 37
  • Phase 40
  • Phase not recorded2
Studied condition
Cancer · Carcinoma, Non-Small-Cell Lung · Clear Cell Renal Cell Carcinoma
Next primary completion
05 February 2027 · estimated
Open drug

Luspatercept

reblozyl

10
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 23
  • Phase 35
  • Phase 41
  • Phase not recorded1
Studied condition
Anemia · Beta-thalassemia · Beta-Thalassemia
Next primary completion
16 July 2027 · estimated
Open drug

Navlimetostat

Canonical investigational asset

10
Active trials
8
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 16
  • Phase 22
  • Phase 32
  • Phase 40
  • Phase not recorded0
Studied condition
Advanced Solid Tumor · Advanced Solid Tumors · Advanced Solid Tumors With Homozygous MTAP Deletion
Next primary completion
Not reported
Open drug

212 of 256 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 212 of 256 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Bristol Myers Squibb trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
BALSAM-1
Xanomeline/Trospium Chloride

NCT06951698

Phase 3 · Recruiting

Trial source and qualifications

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

No eligible observations recorded in the inspected period.

    Start: 11 Jun 2025 · actual
    Primary completion: 01 Nov 2026 · estimated
    Study completion: 01 Nov 2026 · estimated

    2021202220232024202520262027202820292030
    A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
    Xanomeline/Trospium Chloride

    NCT06951711

    Phase 3 · Recruiting

    Trial source and qualifications

    A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

    0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    No eligible observations recorded in the inspected period.

      Start: 13 Jun 2025 · actual
      Primary completion: 02 Nov 2026 · estimated
      Study completion: 02 Nov 2026 · estimated

      2021202220232024202520262027202820292030
      POETYK SjS-1
      Deucravacitinib

      NCT05946941

      Phase 3 · Active, not recruiting

      Trial source and qualifications

      A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

      2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      2 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 11 Sept 2023 · actual
        Primary completion: 18 Nov 2026 · estimated
        Study completion: 16 Nov 2028 · estimated

        2021202220232024202520262027202820292030
        A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
        Xanomeline/Trospium Chloride

        NCT06585787

        Phase 3 · Recruiting

        Trial source and qualifications

        A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

        3 candidate observations · 0 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        3 inspected observations omitted. At most three verified observations are shown, not full history.

          Start: 26 Sept 2024 · actual
          Primary completion: 24 Nov 2026 · estimated
          Study completion: 22 Dec 2026 · estimated

          2021202220232024202520262027202820292030
          A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
          Mezigdomide

          NCT03989414

          Phase 2 · Active, not recruiting

          Trial source and qualifications

          A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

          Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

          Start clipped at the display horizon.

          0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

          ClinicalTrials.gov source

          No eligible observations recorded in the inspected period.

            Start: 30 Sept 2019 · actual
            Primary completion: 30 Nov 2026 · estimated
            Study completion: 30 Nov 2026 · estimated

            2021202220232024202520262027202820292030
            ACTION-1
            Actinium Ac-225 Dotatate

            NCT05477576

            Phase 3 · Active, not recruiting

            Trial source and qualifications

            Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

            Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 4 inspected observations were not displayed.

            6 candidate observations · 2 shown · 0 recorded after primary completion · 4 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

            ClinicalTrials.gov source

            4 inspected observations omitted. At most three verified observations are shown, not full history.

            • enrollment change · Recorded 2026-10-06 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
            • status flip · Recorded 2026-10-06 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

            Start: 24 Mar 2022 · actual
            Primary completion: Dec 2026 · estimated
            Study completion: Dec 2030 · estimated

            2021202220232024202520262027202820292030

            Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

            6 selected of 86 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 30 actual primary completions, 0 untyped primary completions, 11 past estimates, 11 outside the horizon, 0 contradictory dates.

            04 / Therapeutic focus

            Where the activity is

            124

            active trials in Oncology

            Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

            Active trials by primary therapeutic area

            • Oncology124 trials
            • Neurology18 trials
            • Immunology & Inflammation17 trials
            • Psychiatry & Addiction16 trials
            • Cardiovascular15 trials
            • Dermatology13 trials
            • Haematology5 trials
            • Respiratory4 trials
            • Renal & Urology2 trials
            • Unmapped28 trials
            • Healthy volunteers14 trials

            Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

            06 / Related companies

            All companies
            I

            Incyte

            Shared indexed programme context · 1 selected asset

            M

            Merck

            Shared indexed programme context · 1 selected asset

            N

            Novartis

            Shared indexed programme context · 1 selected asset

            Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

            Sources, scope and methodology

            ClinicalTrials.gov lead-sponsor scope

            Enumerated controlled company group covers 2,182 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Bristol-Myers Squibb · Adnexus, A Bristol-Myers Squibb R&D Company · MyoKardia, Inc.. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

            ClinicalTrials.gov

            Attribution coverage

            2,182 distinct registry candidates produced 2,182 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 10 unverified, 10 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

            Indexed enrichment

            1,885 scoped records have indexed enrichment and 297 do not. Missing enrichment does not remove a trial from cohort counts.

            Scope observation

            The successful attribution check completed at 2026-11-01T01:37:53.554Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 3dcb28fc98a1864df3efc0531abb7dc0ca4fd48f473e0b9dcaa3da9a6acc5fa4.

            Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

            Dated canonical-attribution snapshot: 2,182 mapped lead-sponsored clinical studies across all statuses. 1,885 have indexed enrichment, 297 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

            Keep following
            what matters.

            Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

            Build your watch

            Choose what to track in the watch builder.